Genetics of human malignant peripheral nerve sheath tumors. (28th November 2019)

• Record Type: Journal Article
• Authors: Pemov, Alexander; Li, Hua; Presley, William; Wallace, Margaret R; Miller, David T
• Is Part Of: Neuro-oncology advances. Volume 2(2020)Supplement 1
• Page Start: i50
• Page End: i61
• Publication Date: 2019-11-28
• Subjects: Epigenomics -- genomics -- MPNST -- NF1 -- transcriptome; 616.99481
• DOI: 10.1093/noajnl/vdz049
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Malignant peripheral nerve sheath tumors (MPNSTs) are heterogeneous, highly aggressive tumors with no widely effective treatment other than surgery. Genomic architecture of MPNST is similar to other soft tissue sarcomas, with a relatively modest burden of single nucleotide variants and an elevated frequency of copy-number alterations. Recent advances in genomic studies identified previously unrecognized critical involvement of polycomb repressor complex 2 (PRC2) core components SUZ12 and EED in transition to malignancy. Notably, somatic changes in NF1, CDKN2A/B, and PRC2 are found in most MPNST regardless of their etiology (e.g. neurofibromatosis type 1-associated vs. sporadic vs. radiation-induced), indicating that similar molecular mechanisms impact pathogenesis in these neoplasms. The timing and specific order of genetic or epigenetic changes may, however, explain the typically poorer prognosis of NF1-associated MPNSTs. Studies that reveal genes and regulatory pathways uniquely altered in malignancies are essential to development of targeted tumor therapies. Characterization of MPNST molecular profiles may also contribute to tools for earlier detection, and prediction of prognosis or drug response. Here we review the genetic discoveries and their implications in understanding MPNST biology.